ETH-LAD, 6-ethyl-6-nor-lysergic acid diethylamide is an analogue of LSD. Its human psychopharmacology was first described by Alexander Shulgin in the book TiHKAL. ETH-LAD is a psychedelic drug similar to LSD, and is slightly more potent than LSD itself,[2] with an active dose reported at between 20 and 150 micrograms. ETH-LAD has subtly different effects to LSD, described as less demanding. The true tryptamine counterpart of ETH-LAD is MET, a simplified version of this structure.
Clinical data | |
---|---|
Other names | ETH-LAD, 6-ethyl-6-nor-Lysergic acid diethylamide |
Routes of administration | Oral |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Metabolism | Hepatic |
Excretion | Renal |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C21H27N3O |
Molar mass | 337.467 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(what is this?) (verify) |
On June 10, 2014, the UK Advisory Council on the Misuse of Drugs (ACMD) recommended that ETH-LAD be specifically named in the UK Misuse of Drugs Act as a class A drug despite not identifying it as ever having been sold or any harm associated with its use.[3] The UK Home office accepted this advice and announced a ban of the substance to be enacted on 6 January 2015.[4]
ETH-LAD is illegal in Switzerland as of December 2015.[5]